Northstar Response®
Adapt cancer treatment planning in real-time.
Analytical limit
of detection
Targeted
methylation loci
Northstar Response® is a tissue-free, methylation-based assay that enables real-time monitoring with single-molecule precision, detecting subtle shifts in tumor burden at sensitivity down to 0.01% tumor fraction.
Cancer doesn't wait. You need an assay that can stay ahead.
Enhance treatment monitoring with real-time tumor tracking and epigenomic insights from a simple blood draw, enabling earlier, more confident decisions.
Pan-cancer and treatment agnostic response monitoring
Assess epigenomic changes from over 2200 cancer-specific methylation sites
Limit of detection down to 0.01%1 TF for extreme sensitivity, with tissue-free convenience
Quantifiable and precise Tumor Methylation Score (TMS) at every collection
Applicable for all late-stage cancer patients on any treatment regimens
More timely insights to optimize treatment strategy
Imaging remains a key tool but it often lacks the precision or timing needed for real-time decisions. Northstar Response complements imaging by delivering early, actionable signals at the single-molecule level — often weeks in advance.
Monitor between scans
Get real-time feedback on therapy effectiveness without waiting for the next imaging cycle — helping you stay one step ahead.
Clarify imaging results
Use molecular signals to support decision-making when imaging results are unclear or confounded by pseudo-progression or inflammation.
Adapt to changes sooner
Detect subtle changes in tumor burden earlier than traditional tools, allowing for more timely treatment adjustments or escalation.
The only tissue-free treatment monitoring test that achieves single-molecule precision.
The Northstar Response report was designed to easily convey longitudinal monitoring tumor burden trends
for patients on systemic treatment (chemotherapy, immunotherapy, targeted therapy).
Clear result indicators: categorizes whether tumor burden increased, decreased, or remained stable
Precise Tumor Methylation Score™ (TMS): quantifies tumor burden in each sample
Graphical TMS trend: Easily identify trends between collections
About Tumor Methylation
Versus SNV- / Mutation-Based Monitoring Tests
Tumor methylation is a robust, tumor-specific biomarker2,3 that overcomes the limitations of tracking only variant allele fractions (VAF) from a few somatic mutations, as in first-generation ctDNA assays.
As a liquid-only test, it requires no tissue and avoids the delays and complexity of tumor-informed approaches, delivering faster insights into treatment response.
Download Helpful Resources
Analytical validation data on file
Ye, PP., et al. Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring. Sci Rep. 2025 Feb 18;15(1):5869.
Hsiao, A., et al. Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC. Clin Lung Cancer. 2025 Jan;26(1):72-77.
Act with certainty.
Adapt with precision.
